PBM Capital Group, LLC is a private investment firm based in Charlottesville, Virginia, founded in 2010. The firm specializes in healthcare investments, focusing on the pharmaceutical, healthcare, and life sciences sectors. Led by entrepreneur Paul Manning, PBM Capital engages in various investment stages, including venture capital, leveraged buyouts, growth capital, distressed turnaround situations, and public equity value investing. The firm aims to create value by leveraging extensive industry knowledge, providing operational expertise, and fostering an entrepreneurial approach to enhance the success and profitability of its portfolio companies.
Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.
Taysha Gene Therapies
Post in 2023
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.
Lexeo Therapeutics
Series B in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.
Xalud Therapeutics
Series C in 2021
Xalud Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuro-inflammatory diseases and chronic pain management. Established in 2009 and based in San Francisco, California, the company has created a gene therapy platform aimed at addressing conditions such as osteoarthritis and rheumatoid arthritis. Its lead product candidate, XT-150, is currently undergoing clinical trials to evaluate its efficacy in treating osteoarthritis pain. Additionally, Xalud is exploring the potential of another product, XT-101, which is designed to halt disease progression, alleviate neuropathic pain, and reverse paralysis, with research ongoing into its applications for multiple sclerosis and amyotrophic lateral sclerosis. Through innovative strategies, Xalud Therapeutics seeks to provide effective relief for patients suffering from inflammatory joint disorders.
Genapsys
Series D in 2021
GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.
SalioGen Therapeutics
Series A in 2021
SalioGen Therapeutics is a biotechnology company focused on developing gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT), the company employs mammal-derived enzymes, known as Saliogase, to facilitate genome engineering. This innovative approach enables the delivery of any size gene through non-viral methods, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide durable, safe, and affordable treatments, potentially transforming the landscape of care for patients with genetic conditions and enhancing the efficiency of cell therapy and biologics manufacturing in the healthcare sector.
PatientsLikeMe
Venture Round in 2021
PatientsLikeMe, Inc. operates a healthcare data-sharing platform that facilitates the exchange of symptoms, treatments, health data, and personal experiences among patients, caregivers, healthcare professionals, and researchers. Founded in 2004 and based in Cambridge, Massachusetts, the platform serves over 600,000 members and focuses on a broad range of health conditions, including cancer, mental health, and chronic diseases. PatientsLikeMe enables users to discover new treatment options, connect with peers, and engage in health management to enhance their outcomes. The company collaborates with major pharmaceutical firms and government organizations to incorporate patient insights into research, development, and public policy. Additionally, PatientsLikeMe has published over 100 research studies, establishing itself as a credible resource for real-world disease information. It is a subsidiary of United Healthcare Services, Inc.
Lexeo Therapeutics
Series A in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.
Acumen Pharmaceuticals
Series B in 2020
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which is designed to selectively target amyloid-beta oligomers, believed to be a key factor in the progression of Alzheimer's disease. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in the enrollment of patients for clinical trials. The Phase 1 clinical trial for ACU193 began in 2021, aiming to assess its safety, tolerability, and pharmacokinetics in patients with mild cognitive impairment and mild dementia resulting from Alzheimer's disease. Founded in 1996 and based in Livermore, California, Acumen Pharmaceuticals is committed to addressing the challenges posed by Alzheimer’s disease through innovative therapeutic approaches.
Taysha Gene Therapies
Series B in 2020
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.
Verona Pharma
Post in 2020
Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.
Taysha Gene Therapies
Seed Round in 2020
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.
Atsena Therapeutics
Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.
ArcherDX
Series C in 2019
ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.
Landos Biopharma
Series B in 2019
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.
ArcherDX
Series B in 2019
ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.
Candel Therapeutics
Series B in 2019
Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing cancer immunotherapies aimed at enhancing the quality of life for cancer patients and their families. The company specializes in low-toxicity viral immunotherapies that target the prevention of cancer recurrence and progression, particularly for less aggressive cancers such as newly diagnosed prostate cancer. Candel has developed two clinical-stage platforms utilizing novel, genetically modified constructs of adenovirus and herpes simplex virus (HSV). These innovative approaches enable physicians to improve patient outcomes and facilitate quicker recovery, marking a significant advancement in cancer treatment.
Acumen Pharmaceuticals
Series A in 2018
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which is designed to selectively target amyloid-beta oligomers, believed to be a key factor in the progression of Alzheimer's disease. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in the enrollment of patients for clinical trials. The Phase 1 clinical trial for ACU193 began in 2021, aiming to assess its safety, tolerability, and pharmacokinetics in patients with mild cognitive impairment and mild dementia resulting from Alzheimer's disease. Founded in 1996 and based in Livermore, California, Acumen Pharmaceuticals is committed to addressing the challenges posed by Alzheimer’s disease through innovative therapeutic approaches.
Nanoview Biosciences
Series B in 2018
NanoView Biosciences is a biotechnology company that specializes in the development of technologies for the characterization of extracellular vesicles, particularly exosomes. Founded in 2015 and based in Boston, Massachusetts, the company utilizes its proprietary ExoView technology to provide high-throughput and cost-effective analysis solutions for life science researchers. NanoView's products, which include the ExoView R100 and ExoView tetraspanin, enable precise detection and multiparametric characterization of exosomes from complex biological samples such as blood, serum, plasma, and urine. In addition to its core products, the company offers custom assays, sample services, and a support platform to aid researchers in understanding the biological roles of exosomes and utilizing them as biomarkers for disease diagnosis, treatment, and monitoring.
ArcherDX
Series A in 2018
ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.
Breas Medical
Acquisition in 2014
Breas Medical AB specializes in designing, developing, and manufacturing homecare ventilation and sleep therapy products for both adult and pediatric patients with respiratory issues. Founded in 1991 and based in Molnlycke, Sweden, the company offers a range of medical devices, including continuous positive airway pressure devices, pressure control and support devices, life-support ventilators, and sleep apnea therapy devices. These products are intended to assist patients suffering from conditions like neuromuscular disorders, anatomical defects, and pulmonary diseases. Breas Medical also provides clinical services and distributes its products globally through a network of trained distributors and an online store. The company is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.